Corient Private Wealth LP Acquires New Position in Vir Biotechnology, Inc. $VIR

Corient Private Wealth LP bought a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 310,548 shares of the company’s stock, valued at approximately $3,165,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC purchased a new position in Vir Biotechnology during the second quarter valued at approximately $25,034,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Vir Biotechnology in the second quarter worth $4,843,000. Pictet Asset Management Holding SA increased its stake in shares of Vir Biotechnology by 10,878.9% in the first quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock worth $13,268,000 after purchasing an additional 1,467,340 shares in the last quarter. Candriam S.C.A. raised its position in shares of Vir Biotechnology by 10.1% during the 1st quarter. Candriam S.C.A. now owns 1,135,763 shares of the company’s stock valued at $10,176,000 after purchasing an additional 104,100 shares during the period. Finally, ARCH Venture Management LLC bought a new stake in shares of Vir Biotechnology during the 2nd quarter valued at $129,353,521. Institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on VIR shares. Morgan Stanley set a $25.00 target price on shares of Vir Biotechnology in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Wednesday, July 8th. Leerink Partners increased their target price on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. Finally, Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $21.57.

Vir Biotechnology Stock Up 6.3%

Shares of VIR stock opened at $11.63 on Wednesday. The company’s fifty day simple moving average is $9.65 and its two-hundred day simple moving average is $9.37. Vir Biotechnology, Inc. has a 52 week low of $4.75 and a 52 week high of $11.74. The stock has a market cap of $1.97 billion, a P/E ratio of -6.25 and a beta of 1.62.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The firm had revenue of $238.95 million during the quarter, compared to analyst estimates of $135.88 million. During the same quarter last year, the business posted ($0.80) earnings per share. The business’s quarterly revenue was up 19582.5% compared to the same quarter last year. On average, analysts anticipate that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.